Zika virus immunogenic compositions
View Patent ↗Provided herein are methods of use of subunit immunogenic compositions, in particular for the prevention and treatment of Zika virus infections.
1. A method for preventing and/or treating a Zika viral infection in a subject in need thereof, the method comprising:
administering a therapeutically effective amount of an isolated polypeptide comprising an altered structural envelope (E) protein domain III (EDIII);
wherein the isolated polypeptide comprises any of SEQ ID NOs 4-6 or 8-22, or a combination thereof; and
wherein the alteration reduces or prevents the immunogenicity of one or more interfering epitopes of the EDIII.
2. The method of claim 1 further comprising co-administration of an adjuvant.
3. The method of claim 1 , wherein the interfering epitope surrounds residue 333 , 366 , or 375 of ZIKV EDIII polypetide.
4. The method of claim 1 , wherein the alteration comprises creation of a site for N-linked glycosylation.
5. The method of claim 4 , wherein the alteration comprises at least an N at residue 375 and either a T or S at residue 377 .
6. The method of claim 4 , wherein the alteration comprises at least an N at residue 333 and either a T or S at residue 335 .
7. The method of claim 4 , wherein the alteration comprises at least an N at residue 366 and either a T or S at residue 368 .
8. The method of claim 5 , wherein the alteration comprises M375N/E377T.
9. The method of claim 6 , wherein the alteration comprises A333N.
10. The method of claim 7 , wherein the alteration comprises T366N/S368T.
11. The method of claim 1 , wherein the administration decreases viral titer levels, or viral RNA copy number.
12. The method of claim 1 , wherein the administration increases production of neutralizing antibodies.
13. A method for preventing and/or treating a Zika virus infection in a subject in need thereof, the method comprising administering a therapeutically effective amount of an immunogenic composition comprising an isolated polypeptide comprising any of SEQ ID NOs 4-6 or 8-22, or a combination thereof to a subject in need thereof.
14. The method of claim 13 , wherein the subject is a woman who is pregnant, who may become pregnant, or who plans to become pregnant.
15. The method of claim 13 , wherein the administration increases production of neutralizing antibodies.
16. The method of claim 13 , wherein the administration decreases viral titer levels, or viral RNA copy number.
17. The method of claim 14 , wherein as a result of the administration, any pregnancy in the woman does not result in Zika virus-associated birth defects.